Cubist’s Cubicin gets boost from expanded indication

The FDA has approved broader use for Cubist Pharmaceuticals’ Cubicin intravenous antibiotic to also treat bloodstream infections, including a form of endocarditis. Cubist plans to market Cubicin for the new indication immediately, the Lexington, MA-firm said. Cubicin was originally approved in late 2003, for the treatment of complicated skin and skin structure infection and has reached $100 million in sales since then. In November 2005, the company announced it would boost the size of its hospital sales force from 99 to 135 in anticipation of today’s regulatory approval.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.